Sublingual apomorphine in the treatment of Parkinson's disease.
Apomorphine
Clinical trials
Levodopa
On demand medication
Parkinson´s disease
Sublingual application
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
01
03
2024
accepted:
04
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
Advanced Parkinson´s disease (PD) is often complicated by fluctuations of disability depending on plasma levels of levodopa. For most patients OFF phases with worsening of tremor and immobility, but also pain, depression, autonomic symptoms are troublesome. While adjustments of levodopa administrations can relief such fluctuations for some time, "on demand" therapies become more and more important. These "on demand" therapies should provide fast and efficacious relief. During the past years, new options for on demand therapies in PD-associated OFF episodes have been developed, including new formulations of levodopa and apomorphine to provide fast and readily accessible on demand treatment. In this narrative review, the challenges of the treatment of PD-associated fluctuations and OFF states are addressed, with a special focus on sublingual apomorphine (SL-APO) including the results from recent clinical trials.
Identifiants
pubmed: 38743091
doi: 10.1007/s00702-024-02777-z
pii: 10.1007/s00702-024-02777-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Antonini A, Jenner P (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14(12):693–694. https://doi.org/10.1038/s41582-018-0083-y
doi: 10.1038/s41582-018-0083-y
pubmed: 30279608
Buhmann C, Bihler M, Emich K, Hidding U, Pötter-Nerger M, Gerloff C, Niessen A, Flügel T, Koseki JC, Nienstedt JC, Pflug C (2019) Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism Relat Disord 62:51–56. https://doi.org/10.1016/j.parkreldis.2019.02.002
doi: 10.1016/j.parkreldis.2019.02.002
pubmed: 30770254
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s Disease: efficacy and safety of current and new formulations. CNS Drugs 33:905–918. https://doi.org/10.1007/s40263-019-00661-z
doi: 10.1007/s40263-019-00661-z
pubmed: 31473980
pmcid: 6776563
Chen JJ, Obering C (2005) A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson’s disease. Clin Ther 27(11):1710–1724. https://doi.org/10.1016/j.clinthera.2005.11.016
doi: 10.1016/j.clinthera.2005.11.016
pubmed: 16368444
Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F (2018) The spectrum of off in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord 51:9–16. https://doi.org/10.1016/j.parkreldis.2018.02.001
doi: 10.1016/j.parkreldis.2018.02.001
pubmed: 29456046
Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the treatment of Parkinson’s Disease: I. Invasive therapies. Mov Disord 37:1360–1374. https://doi.org/10.1002/mds.29066
doi: 10.1002/mds.29066
pubmed: 35791767
Fabbri M, Barbosa R, Rascol O (2023) Off-time Treatment options for Parkinson’s Disease. Neurol Ther 12:391–424. https://doi.org/10.1007/s40120-022-00435-8
doi: 10.1007/s40120-022-00435-8
pubmed: 36633762
pmcid: 10043092
Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimarães B, Rocha JF, Soares-da-Silva P (2022) Effect of Opicapone on Levodopa Pharmacokinetics in patients with fluctuating Parkinson’s Disease. Mov Disord 37:2272–2283. https://doi.org/10.1002/mds.29193
doi: 10.1002/mds.29193
pubmed: 36054562
pmcid: 9804871
Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832. https://doi.org/10.1002/mds.22112
doi: 10.1002/mds.22112
pubmed: 19191340
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C (2020) Inhaled levodopa in Parkinson’s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord 71:4–10. https://doi.org/10.1016/j.parkreldis.2019.12.012
doi: 10.1016/j.parkreldis.2019.12.012
pubmed: 31927343
Hauser RA, Auinger P, Oakes D, Parkinson Study Group (2009) Levodopa response in early Parkinson’s disease. Mov Disord 24:2328–2336. https://doi.org/10.1002/mds.22759
doi: 10.1002/mds.22759
pubmed: 19908302
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A (2016) Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 31:1366–1372. https://doi.org/10.1002/mds.26697
doi: 10.1002/mds.26697
pubmed: 27430123
Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D’Souza R (2023A) IPX203 vs Immediate-Release Carbidopa-Levodopa for the treatment of Motor fluctuations in Parkinson Disease: the RISE-PD Randomized Clinical Trial. JAMA Neurol 80:1062–1069. https://doi.org/10.1001/jamaneurol.2023.2679
Hauser RA, Ondo WG, Zhang Y, Bowling A, Navia B, Pappert E, Isaacson SH, CTH-301 Study Investigators (2023B) Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? J Parkinsons Dis 13:403–414. https://doi.org/10.3233/JPD-223537
Höllerhage M, Klietz M, Höglinger GU (2022) Disease modification in parkinsonism: obstacles and ways forward. J Neural Transm (Vienna) 129:1133–1153. https://doi.org/10.1007/s00702-022-02520-6
doi: 10.1007/s00702-022-02520-6
pubmed: 35695938
Hui JS, Fox SH, Neeson W, Bhargava P, Pappert E, Blum D, Navia B, CTH-300 Study Investigators (2020) Open-label titration of apomorphine sublingual film in patients with Parkinson’s disease and OFF episodes. Parkinsonism Relat Disord 79:110–116. https://doi.org/10.1016/j.parkreldis.2020.08.028
doi: 10.1016/j.parkreldis.2020.08.028
pubmed: 32927285
Isaacson SH, Achari M, Bhidayasiri R, Comella C, Farmer JG, Gupta F, Jones S, Kreitzman D, Kremens D, Lewis SJG, Poewe W, Tolosa E, Campos C, Gibbs SN, Broder MS (2023A) Expert Consensus on the Use of On-Demand Treatments for OFF Episodes in Parkinson’s Disease: A Modified Delphi Panel. Mov Disord Clin Pract 10:652–657. https://doi.org/10.1002/mdc3.13690
Isaacson SH, Bowling A, Zhang I, Pappert E, Stocchi F, CTH-300 and CTH-301 Study Investigators (2023B) Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. Neurodegener Dis Manag 13:75–84. https://doi.org/10.2217/nmt-2022-0038
Jost WH, Ebersbach G, Kassubek J, Klebe S, Tönges L (2021) New Therapeutic options for the individualised titration of levodopa. Fortschr Neurol Psychiatr 89:23–28. https://doi.org/10.1055/a-1158-9281
doi: 10.1055/a-1158-9281
pubmed: 32462651
Jost WH, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, Tönges L, Woitalla D, Reichmann H (2022) Relevance of COMT inhibitors in the treatment of motor fluctuations. Nervenarzt 93:1035–1045. https://doi.org/10.1007/s00115-021-01237-3
doi: 10.1007/s00115-021-01237-3
pubmed: 35044481
Jost WH, Kulisevsky J, LeWitt PA Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease. J Neural Transm (Vienna) 130:821–826. https://doi.org/10.1007/s00702-023-02636-3
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
doi: 10.1016/S0140-6736(14)61393-3
pubmed: 25904081
Kassubek J, Stocchi F, Balaguer Martinez E, Pahwa R, Ondo W, Zhang Y, Bowling A, Pappert E, Isaacson S, Wu S, for the CTH-302 Study Investigators (2023) Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose optimization phase of an open-label, randomized crossover study. Ther Adv Neurol Disord 16:17562864231209240. https://doi.org/10.1177/17562864231209240
doi: 10.1177/17562864231209240
pubmed: 37954918
pmcid: 10637145
Labeit B, Berkovich E, Claus I, Roderigo M, Schwake AL, Izgelov D, Mimrod D, Ahring S, Oelenberg S, Muhle P, Zentsch V, Wenninger F, Suntrup-Krueger S, Dziewas R, Warnecke T (2022) Dysphagia for medication in Parkinson’s disease. NPJ Parkinsons Dis 8:156. https://doi.org/10.1038/s41531-022-00421-9
doi: 10.1038/s41531-022-00421-9
pubmed: 36371409
pmcid: 9653428
Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HÇ, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, Stocchi F, Jenner P, Warnecke T, Ray Chaudhuri K (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson’s disease. Eur J Neurol 30:1465–1480. https://doi.org/10.1111/ene.15734 . International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group
doi: 10.1111/ene.15734
pubmed: 36757008
LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145–154. https://doi.org/10.1016/S1474-4422(18)30405-8
doi: 10.1016/S1474-4422(18)30405-8
pubmed: 30663606
Olanow CW (2019) Levodopa is the best symptomatic therapy for PD: nothing more, nothing less. Mov Disord 34:812–815. https://doi.org/10.1002/mds.27690
doi: 10.1002/mds.27690
pubmed: 30990922
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators (2020) Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19:135–144. https://doi.org/10.1016/S1474-4422(19)30396-5
doi: 10.1016/S1474-4422(19)30396-5
pubmed: 31818699
Olanow CW, Poewe W, Rascol O, Stocchi F (2021A) On-Demand Therapy for OFF Episodes in Parkinson’s Disease. Mov Disord 36:2244–2253. https://doi.org/10.1002/mds.28726
Olanow CW, Stocchi F, Peckham EL, De Pandis MF, Sciarappa K, Navia B (2021B) Dose optimization of apomorphine sublingual film for treating OFF episodes in Parkinson’s disease. Parkinsonism Relat Disord 93:27–30. https://doi.org/10.1016/j.parkreldis.2021.10.025
Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L (2019) Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna) 126:879–888. https://doi.org/10.1007/s00702-019-02034-8
doi: 10.1007/s00702-019-02034-8
pubmed: 31222604
Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123:2297–2305. https://doi.org/10.1093/brain/123.11.2297
doi: 10.1093/brain/123.11.2297
pubmed: 11050029
Stacy M (2010) The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease. J Neural Transm (Vienna) 117:837–846. https://doi.org/10.1007/s00702-010-0424-5
doi: 10.1007/s00702-010-0424-5
pubmed: 20563826
Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G, DEEP study group (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204–211. https://doi.org/10.1016/j.parkreldis.2013.10.027
doi: 10.1016/j.parkreldis.2013.10.027
pubmed: 24275586
Stocchi F, Peckham EL, De Pandis MF, Sciarappa K, Kleiman R, Agbo F, Olanow CW, Blum D, Navia B (2022) A Randomized Thorough QT Study of Apomorphine Sublingual Film in patients with Parkinson’s Disease. Clin Pharmacol Drug Dev 11:1068–1077. https://doi.org/10.1002/cpdd.1147
doi: 10.1002/cpdd.1147
pubmed: 35899977
pmcid: 9541463
Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Manzanares LL, Zhang Y, Bowling A, Pappert E, Wu S, for the CTH-302 Study Investigators (2023) Apomorphine Sublingual Film compared with Subcutaneous Apomorphine for OFF episodes in Parkinson’s disease: an Open-label, randomized, crossover study. J Parkinsons Dis 13:1329–1342. https://doi.org/10.3233/JPD-230072
doi: 10.3233/JPD-230072
pubmed: 37980683
pmcid: 10741320
Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80:800–809. https://doi.org/10.1212/WNL.0b013e318285c0ed
doi: 10.1212/WNL.0b013e318285c0ed
pubmed: 23365054
Williams LJ, Griffith J, Waller SE, Kwan VP, Fung VSC (2022) The profound impact of gastrointestinal stasis on Levodopa Response in Parkinson’s Disease. Mov Disord Clin Pract 9:394–396. https://doi.org/10.1002/mdc3.13425
doi: 10.1002/mdc3.13425
pubmed: 36952652
pmcid: 8974886
Zhang Y, He X, Mo C, Liu X, Li J, Yan Z, Qian Y, Lai Y, Xu S, Yang X, Xiao Q (2022) Association between Microbial Tyrosine Decarboxylase Gene and Levodopa responsiveness in patients with Parkinson Disease. Neurology 99:e2443–e2453. https://doi.org/10.1212/WNL.0000000000201204
doi: 10.1212/WNL.0000000000201204
pubmed: 36240098